Xolair is manufactured in Switzerland and shipped by our pharmacy in India by courier.
Information about Xolair (Omalizumab)
Xolair is a monoclonal antibody that works by targeting and inhibiting the action of immunoglobulin E (IgE), an antibody involved in allergic reactions. It is used to treat conditions like asthma and chronic hives, particularly in patients whose symptoms are not adequately controlled by other medications. By reducing IgE levels, Xolair helps prevent allergic responses and inflammation that lead to asthma attacks or allergic skin reactions.
Product Highlights
- Xolair is used for patients with asthma that is driven by allergic triggers, helping to reduce asthma attacks and improve lung function.
- Xolair is used to treat chronic hives in patients who do not respond well to antihistamines.
- Xolair is prescribed to patients with chronic rhinosinusitis and nasal polyps, which are often linked to allergic inflammation.
Key Ingredient
Key Benefits
- Xolair helps reduce the frequency and severity of asthma attacks in patients with allergic asthma.
- For patients with chronic hives (urticaria), Xolair helps reduce itching and the appearance of hives, improving quality of life.
- In patients with allergic asthma, Xolair can help improve overall lung function and reduce reliance on other asthma medications.
- The effects of Xolair last for a longer period, helping to control symptoms between injections.
Direction of Use
- The dosage of Xolair depends on the condition being treated, the patient's weight, and the specific medical guidelines. For asthma, the dose is typically given every 2 to 4 weeks.
- For asthma: Xolair is typically administered every 2 to 4 weeks, with the dose varying based on body weight.
- For chronic hives: A typical dosing schedule might be every 2 to 4 weeks, but this can be adjusted depending on response.
- Xolair is given by subcutaneous injection, often performed in a healthcare setting under the supervision of a medical professional.
- Regular monitoring by a healthcare provider is necessary to evaluate the medication's effectiveness and to manage any potential side effects.
Safety Concerns
- Though rare, Xolair can cause serious allergic reactions, including anaphylaxis. Patients are typically monitored after the first few injections to detect any immediate allergic reactions.
- Xolair may increase the risk of certain infections, including upper respiratory infections, sinus infections, and viral infections. Patients should inform their doctor if they experience symptoms of an infection.
- Some people may experience pain, redness, or swelling at the injection site.
- There have been reports of a slightly increased risk of certain types of cancer in patients using Xolair, though the connection is not definitively established.
- There is a potential for cardiovascular side effects, so patients with heart issues should be monitored.
- Xolair is not used to treat acute asthma attacks or anaphylaxis. It should be used as a long-term maintenance treatment.
Avoid Xolair (Omalizumab) If
- If you are allergic to omalizumab or any of the ingredients in Xolair, do not use this medication.
- If you have had a severe allergic reaction to other monoclonal antibody therapies, discuss with your doctor whether Xolair is appropriate.
- Xolair should only be used during pregnancy or breastfeeding if the potential benefits outweigh the risks. Speak to your healthcare provider about alternatives and the safest approach.
- Xolair is not suitable for acute asthma attacks. It should not be used to treat emergency situations or as a replacement for fast-acting bronchodilators.
- If you have an active infection, especially severe or chronic, consult your doctor before using Xolair, as it may increase the risk of infections.
This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.
